Nemaura Medical announces licensing deal with DB Pharma (Jersey) Ltd

Nemaura Medical announces licensing deal with DB Pharma (Jersey) Ltd., for its unique non-invasive wireless continuous glucose monitoring Watch for the UK and Ireland.

Nemaura Medical Inc., a company developing a non-invasive, wireless, transdermal continuous glucose monitoring (CGM) Watch announced today that the Company has made a significant step towards commercializing its CGM Watch in the UK after signing a license agreement granting DB Pharma (Jersey) Ltd., sole and exclusive rights to market its CGM Watch in the UK and Republic of Ireland once the product receives CE approval which is anticipated for 2015.

DB Pharma Ltd., is part of a specialist Pharma company (group) involved in the marketing and distribution of prescription Pharmaceutical and healthcare products throughout the UK, with an excellent track record of successfully bringing new products to market, rapidly and cost-effectively. There are approximately 144,000 patients in the UK who are solely insulin dependent who rely on taking blood glucose measurements using invasive painful finger prick testing 6-8 times a day, and in addition there are in excess of 270,000 mature onset diabetics who also require insulin, and regular blood glucose monitoring. The CGM device is expected to provide patients with a pain-free user friendly and cost-effective alternative to traditional routine finger prick measurements